ARTICLE

Received 16 Sep 2011 | Accepted 7 Mar 2012 | Published 10 Apr 2012

DOI: 10.1038/ncomms1776

CYLD negatively regulates transforming growth factor- β -signalling via deubiquitinating Akt

Jae Hyang Lim^{1,2,*}, Hirofumi Jono^{2,3,*}, Kensei Komatsu^{1,2}, Chang-Hoon Woo⁴, Jiyun Lee^{1,2}, Masanori Miyata^{1,2}, Takashi Matsuno^{1,2}, Xiangbin Xu², Yuxian Huang⁵, Wenhong Zhang⁵, Soo Hyun Park⁶, Yu-Il Kim⁷, Yoo-Duk Choi⁸, Huahao Shen⁹, Kyung-Sun Heo¹⁰, Haodong Xu¹¹, Patricia Bourne¹¹, Tomoaki Koga², Haidong Xu^{1,2}, Chen Yan¹⁰, Binghe Wang¹², Lin-Feng Chen¹³, Xin-Hua Feng^{14,15} & Jian-Dong Li^{1,2}

Lung injury, whether induced by infection or caustic chemicals, initiates a series of complex wound-healing responses. If uncontrolled, these responses may lead to fibrotic lung diseases and loss of function. Thus, resolution of lung injury must be tightly regulated. The key regulatory proteins required for tightly controlling the resolution of lung injury have yet to be identified. Here we show that loss of deubiquitinase CYLD led to the development of lung fibrosis in mice after infection with *Streptococcus pneumoniae*. CYLD inhibited transforming growth factor- β -signalling and prevented lung fibrosis by decreasing the stability of Smad3 in an E3 ligase carboxy terminus of Hsc70-interacting protein-dependent manner. Moreover, CYLD decreases Smad3 stability by deubiquitinating K63-polyubiquitinated Akt. Together, our results unveil a role for CYLD in tightly regulating the resolution of lung injury and preventing fibrosis by deubiquitinating Akt. These studies may help develop new therapeutic strategies for preventing lung fibrosis.

¹ Center for Inflammation, Immunity & Infection and Department of Biology, Georgia State University, Atlanta, 30303, USA. ² Department of Microbiology & Immunology, University of Rochester Medical Center, New York 14642, USA. ³ Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, 862-0973, Japan. ⁴ Department of Pharmacology, College of Medicine, Yeungnam University, Daegu 705-717, Korea. ⁵ Department of Infectious Disease, Huashan Hospital, Fudan University, Shanghai 200040, China. ⁶ Department of Veterinary Physiology, College of Veterinary Medicine, Chonnam National University, Gwangju 500-757, Korea. ⁷ Internal Medicine, Gwangju 500-757, Korea. ⁸ Pathology, Chonnam National University & Hospital, Gwangju 500-757, Korea. ⁹ Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine and State Key Lab of Respiratory Diseases, Hangzhou 310009, China. ¹⁰ Cardiovascular Research Institute, University of Rochester Medical Center, New York 14642, USA. ¹¹ Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, New York 14642, USA. ¹² Department of Chemistry & Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, 30303, USA. ¹³ Department of Biochemistry, College of Medicine, University of Illinois at Urbana-Champaign, 61801, USA. ¹⁴ Life Sciences Institute, Zhejiang University, Hangzhou 310058, China. ¹⁵ Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to J.D.L. (email: jdli@gsu.edu).

Lung injury represents a major cause of morbidity and mortality worldwide. Injurious stimuli such as infectious agents and caustic chemicals initiate a complex and dynamic series of host wound-healing responses. During the early stage of severe *Streptococcus pneumoniae* infections, pneumolysin induces acute lung injury (ALI) and lethality. As a critical host response, type 1 plasminogen activator inhibitor (PAI-1) is upregulated by *S. pneumoniae*, which provides protection against ALI by preventing alveolar hemorrhage¹. Appropriate host response such as upregulated PAI-1 production is thus critical for repairing injured lung tissue and restoring its function. However, if uncontrolled, excessive PAI-1 will have an adverse effect on tissue remodelling process via enhanced accumulation of extracellular matrix in tissues^{2–9}. Thus, PAI-1 expression must be tightly and dynamically regulated during the entire host wound-healing process. We previously found that deubiquitinase CYLD has a critical role in preventing excessive production of PAI-1 by suppressing its p38 MAPK-dependent expression. However, during lethal *S. pneumoniae* infection, excessive release of pneumolysin caused severe lung injury, which overwhelms the protective effect of available PAI-1, thereby leading to lethality. Interestingly, CYLD deficiency in the *Cyld*-deficient mouse results in excessive production of PAI-1, thus providing efficient protection against lethality¹. Therefore, our previous study demonstrates that CYLD is a critical negative regulator for host survival during early stage of infection as *Cyld*-deficient mice have a much higher survival rate compared with wild-type (WT) mice. Because uncontrolled and excessive wound-healing response such as excessive PAI-1 production could result in lung fibrosis³, we hypothesized that *Cyld*-deficient mice that survived lethal *S. pneumoniae* infection may develop lung fibrosis, and CYLD may thus act as a key regulator for the wound-healing process during the late stage of bacterial infections. Here we show that CYLD acts as a critical negative regulator for injury-induced fibrotic response by inhibiting transforming growth factor- β (TGF- β)-signalling. We further show that CYLD inhibits TGF- β -signalling via decreasing the stability of Smad3 protein in a glycogen synthase kinase3- β (GSK3 β)-Hsc70-interacting protein (CHIP)-dependent manner. Interestingly, CYLD decreases Smad3 stability by directly deubiquitinating K63-polyubiquitinated Akt. These studies may bring new insights into the novel role of CYLD in regulating fibrosis and may lead to the identification of new therapeutic targets for treating these diseases.

Results

CYLD is a key negative regulator for lung fibrosis. To test our hypothesis, we first determined whether CYLD deficiency leads to the development of lung fibrosis in a mouse model of lung injury induced by *S. pneumoniae* infection. As shown in Fig. 1a, the majority of WT mice that survived ALI appeared fully recovered without significant pathological changes. In contrast, *Cyld*^{-/-} mice exhibited marked fibrotic pathological changes as evaluated by performing H&E staining. Further, histological analysis with Trichrome staining demonstrated significant collagen deposition (stained blue) in lungs of *S. pneumoniae*-inoculated *Cyld*^{-/-} mice but not in WT mice. Moreover, *S. pneumoniae*-inoculated lungs of *Cyld*^{-/-} mice also exhibited a hyperfibrotic response, with increased expression of fibrogenic gene type I and type III collagens (COL1A2 and COL3A1), connective tissue growth factor (CTGF) and PAI-1 compared with WT mouse lung (Fig. 1b). Similar to the lethal dose of *S. pneumoniae*, a sub-lethal dose of *S. pneumoniae* still exhibited a fibrotic effect, and the fibrotic response was significantly enhanced in *Cyld*^{-/-} mice compared with WT mice (Supplementary Fig. S1a). Thus, it is evident that, regardless of the severity of infection, CYLD has a critical role in tightly controlling the fibrotic response and preventing fibrosis.

On the basis that CYLD acts as a negative regulator for PAI-1 upregulation by inhibiting p38 MAPK-dependent PAI-1 expression¹,

we first determined whether CYLD inhibits *S. pneumoniae*-induced lung fibrosis also via inhibiting p38 MAPK signalling. Interestingly, treatment with p38-specific inhibitor SB203580 did not affect lung fibrosis in these *Cyld*^{-/-} mice (Supplementary Fig. S1b). This unexpected finding thus led us to focus on determining a p38-independent molecular mechanism by which CYLD prevents development of lung fibrosis post-bacterial-infection.

Among a number of signalling pathways involved in lung fibrosis, TGF- β -Smad signalling is crucial for regulating lung fibrosis, and *S. pneumoniae* has been shown to induce TGF- β -signalling^{10–15}. Thus, we first determined whether *S. pneumoniae* induces TGF- β -expression. As shown in Supplementary Fig. S1c, *S. pneumoniae* induced TGF- β expression at late stage of infection when fibrosis develops, whereas it induced rapid p38 MAPK activation at early stage when lung injury is induced, followed by inactivation at late stage. These interesting results may well explain why inhibition of p38 using a specific inhibitor did not affect lung fibrosis in *Cyld*^{-/-} mice and may also imply an important role of TGF- β -Smad in mediating *S. pneumoniae*-induced lung fibrosis.

To further determine the clinical relevance of our finding in the mouse model, the expression level of CYLD protein in the lung of human patients with lung fibrosis was measured and compared with that in normal controls. As shown in Fig. 1c; Supplementary Fig. S2a, CYLD expression in the lung tissues with fibrosis was much lower compared with that in normal control. We next sought to explore why CYLD protein level is lower in patients with fibrosis. Because TGF- β -expression was found to be upregulated at a later stage of infection during recovery process from tissue injury, we sought to determine whether TGF- β regulates CYLD expression. Indeed, the expression of CYLD was inhibited by TGF- β in the lung tissue of mice (Supplementary Fig. S2b). Thus, it is logical to propose that TGF- β may promote tissue fibrosis not only by activating the TGF- β -Smad signalling pathway, the critical positive regulator for fibrotic response, but may also, at least in part, by inhibiting the expression of CYLD, the negative regulator for fibrotic response. How TGF- β regulates CYLD needs to be further investigated in the future studies.

To further evaluate the generalizability of our findings, we next sought to determine whether CYLD also acts as a key negative regulator for chemical-induced lung fibrosis in a widely used lung fibrosis model induced by bleomycin. Interestingly, as shown in Supplementary Fig. S3, bleomycin-induced lung fibrosis was also significantly enhanced in *Cyld*-deficient mice compared with WT mice. These data thus suggest that the anti-fibrotic effect of CYLD via inhibiting TGF- β -signalling may be generalizable for tissue fibrosis induced by other injurious stimuli as well.

CYLD prevents lung fibrosis via inhibiting TGF- β -signalling.

Because *S. pneumoniae* induces TGF- β -signalling and TGF- β -signalling is known as a crucial signalling pathway involved in the development of lung fibrosis^{10–16}, we determined whether CYLD inhibits TGF- β -signalling using various approaches including short interfering RNA (siRNA). As expected, siRNA-CYLD (siCYLD) efficiently reduced endogenous CYLD protein expression in a number of cell types including human primary bronchial epithelial NHBE cells and greatly enhanced TNF- α -induced activation of NF- κ B-Luc activity, as previously shown (Fig. 2a,b). Interestingly, CYLD knockdown with siCYLD markedly enhanced the activity of TGF- β -induced Smad-binding element (SBE)-dependent promoter and TGF- β -responsive PAI-1 promoter activity as well as PAI-1 messenger RNA in human lung epithelial A549 and HeLa cells (Fig. 2c,d). Consistent with these results, siCYLD enhanced, whereas overexpressing WT-CYLD, inhibited TGF- β -induced SBE-dependent promoter activity in a dose-dependent manner (Fig. 2e). We next confirmed this finding in human primary bronchial epithelial NHBE cells. As shown in Fig. 2f, siCYLD enhanced, whereas overexpressing WT-CYLD inhibited, TGF- β -induced SBE-Luc

Figure 1 | CYLD is a negative regulator for lung fibrosis in mouse and human. (a) H&E and Masson's trichrome (Trichrome) staining of lung tissues from *Cyld*^{+/+} and *Cyld*^{-/-} mice 2-weeks post *S. pneumoniae* infection (insert: $\times 400$). Scale bars correspond to 200 μ m. (b) Relative quantity of mRNA expression of type I and type III collagens (COL1A2 and COL3A1), CTGF and type 1 plasminogen activator inhibitor (PAI-1) compared with internal control Glyceraldehyde 3-phosphate dehydrogenase was measured in the lung tissues of *Cyld*^{+/+} and *Cyld*^{-/-} mice 2-weeks post *S. pneumoniae* infection. * $P < 0.05$ values are the means $\pm$ s.d. ($n = 3$). Un-paired Student's *t*-test was used for comparison with *Cyld*^{+/+}. (c) H&E, Masson's trichrome, and anti-CYLD staining of control (Con) and lung fibrosis tissues of human patients (Fibrotic lung). Lung fibrosis tissues were obtained from the patients with pulmonary fibrosis, during pneumonectomy, and normal control tissues were obtained from the patient with pneumothorax during the surgery. Slides are representative of 5 (Con) and 10 (Fibrotic) human lung tissues. Scale bars, 200 μ m.

activity in NHBE cells. Consistent with the results obtained using siCYLD, CYLD deficiency also enhanced TGF- β -induced SBE-Luc activation in *Cyld*^{-/-} mouse embryonic fibroblast (MEF) cells as compared with WT MEF (Fig. 2g). Moreover, CYLD deficiency also markedly enhanced induction of TGF- β -regulated fibrogenic genes in mouse lung tissue, including PAI-1 and CTGF (Fig. 2h). We conclude from these data that CYLD negatively regulates TGF- β -signalling both *in vitro* and *in vivo*. We further investigated whether CYLD deficiency leads to lung fibrosis via enhancement of TGF- β -signalling by using SB431542, a specific inhibitor of TGF- β -signalling. Indeed, as shown in Fig. 2i, systemic inoculation of SB431542 inhibited lung fibrosis in *S. pneumoniae*-inoculated *Cyld*^{-/-} lungs, thereby confirming that CYLD deficiency leads to pulmonary fibrosis in post bacterial infections via enhancing TGF- β -signalling.

CYLD inhibits TGF- β -signalling via decreasing Smad3 stability. Having identified CYLD as a negative regulator of TGF- β -signalling

and lung fibrosis, we next sought to determine how CYLD inhibits TGF- β -signalling. TGF- β -ligands bind to a type II receptor (T β RII), which recruits and phosphorylates a type I receptor (T β RI). The activated T β RI then phosphorylates the Smad subgroup known as receptor-activated Smads (R-Smad), for example, Smad3, which can bind to Co-Smad Smad4. The R-Smad and Co-Smad complex then undergoes nuclear translocation for target gene regulation^{17–20}. To first determine at which level CYLD inhibits TGF- β -signalling, we took advantage of the available lung epithelial cell lines, DR26 and R1B that are derived from the WT Mv1Lu cells and lack functional T β RII and T β RI, respectively²¹. As shown in Fig. 3a, siCYLD markedly enhanced constitutively active (C/A)-T β RI-induced SBE-Luc activity in T β RII-deficient DR26 cells, suggesting enhancement of TGF- β -signalling, by CYLD knockdown, occurs at the level or downstream of T β RI independent of T β RII. We next determined whether CYLD exerts its inhibitory effect on TGF- β -signalling at the level or downstream of T β RI by assessing the effects of siCYLD

Figure 2 | CYLD prevents development of lung fibrosis via inhibition of TGF- β -signalling. (a) Epithelial cells transfected with siRNA-Control (siCon) or siCYLD were analysed by immunoblotting with the indicated antibodies. (b) NF- κ B-promoter activity was determined in siCon- or siCYLD-transfected cells stimulated with TNF- α (10 ng ml⁻¹). (c) SBE-promoter and PAI-1-promoter activity was determined in siRNA-control (siCon) or siCYLD-transfected cells stimulated with TGF- β . (d) Relative quantity of PAI-1 mRNA expression compared with Glyceraldehyde 3-phosphate dehydrogenase was measured in siCon- or siCYLD-transfected cells stimulated with TGF- β . (e) SBE-promoter activity was determined in A549 cells transfected with various amount of siCYLD or WT-CYLD and stimulated with TGF- β . (f) SBE-promoter activity was determined in siCYLD or WT-CYLD-transfected human primary bronchial epithelial NHBE cells stimulated with TGF- β . (g) SBE-promoter activity was determined in mouse MEFs from *Cyld*^{+/+} and *Cyld*^{-/-} mice stimulated with TGF- β . (h) Relative quantity of mRNA expression of PAI-1 and CTGF compared with Glyceraldehyde 3-phosphate dehydrogenase was measured in the lung tissues of *Cyld*^{+/+} and *Cyld*^{-/-} mice 6-h post-i.t. inoculation of TGF- β (25–100 ng per mouse). **P* < 0.05 values in (b–h) are the means $\pm$ s.d. (*n* = 3). Statistical data analysis was performed using Student's *t*-test. (i) H&E and Masson's trichrome staining of lung tissues from *Cyld*^{-/-} mice 2-weeks post-*S. pneumoniae*-infection with or without intraperitoneal inoculation of SB431542 (10 mg per kg body weight). Scale bars, 200 μ m.

on WT-Smad3-induced SBE-Luc activity in T β RI-deficient R1B cells. CYLD knockdown markedly enhanced WT-Smad3-induced SBE-Luc activation in R1B cells, suggesting CYLD may inhibit TGF- β -signalling at the level or downstream of Smad3 independent of T β RI (Fig. 3b). To further determine whether CYLD inhibits TGF- β -signalling by likely targeting Smad3, we next evaluated the effect of CYLD knockdown in Smad3-deficient MEF cells. As shown in Fig. 3c, siCYLD did not enhance SBE-Luc activity in the absence of Smad3. In contrast, siCYLD markedly enhanced SBE-Luc activity in cells reconstituted with WT-Smad3, suggesting CYLD may inhibit TGF- β -signalling at the level of, or downstream of, Smad3.

To further determine how CYLD inhibits TGF- β -signalling via Smad3, we next evaluated the effect of CYLD on Smad3 activation by using antibody against phosphorylated Smad3. Interestingly, CYLD knockdown increased, whereas overexpressing WT-CYLD, inhibited not only phosphorylated but also total Smad3 (Fig. 3d). Smad3 expression is also higher in both *Cyld*^{-/-} MEF and *Cyld*^{-/-} mouse lung compared with their WT counterparts (Fig. 3e), whereas another R-Smad Smad2 expression was unaffected by CYLD deficiency (Fig. 3f). Consistent with these results, Smad3 expression was also higher in the lung of human patients with pulmonary fibrosis as compared with normal control (Fig. 3g; Supplementary Fig. S2a).

Figure 3 | CYLD inhibits TGF- β -signalling via decreasing stability of Smad3 protein. (a) SBE-promoter activity was determined in siCon- or siCYLD-transfected T β RII-deficient DR26 cells co-transfected with control vector or constitutively active (C/A)-T β RI. (b) SBE-promoter activity was determined in siCON- or siCYLD-transfected T β I-deficient R1B cells co-transfected with control vector or WT-Smad3. (c) SBE-promoter activity was determined in siCON- or siCYLD-transfected *Smad3*^{-/-} MEF cells, co-transfected with control vector or WT-Smad3. (d) Cells transfected with siCYLD or WT-CYLD were treated with TGF- β and analysed by immunoblotting with the indicated antibodies. (e,f) MEF cells and lung tissues from *Cyld*^{+/+} and *Cyld*^{-/-} mice were analysed by immunoblotting with the indicated antibodies. (g) Lung tissues from control (Con) and lung fibrosis patients (Fibrotic lung) were stained against Smad3 (Left panels, $\times 100$; right panels, $\times 400$). Scale bars, 200 μ m. (h) Cells transfected with WT-CYLD with (right panel) or without Flag-WT-Smad3 (left panel) were analysed by immunoblotting with the indicated antibodies. (i) Relative quantity of mRNA expressions of PAI-1, CTGF, and Smad3 compared with Glyceraldehyde 3-phosphate dehydrogenase was measured in A549 cells transfected with siCON or siCYLD and stimulated with TGF- β . (j) Cells transfected with control vector or WT-CYLD were treated with MG132 (20 μ M) and analysed by immunoblotting with the indicated antibodies. (k) Cells transfected with WT-CYLD were pre-treated with MG-132, and relative quantity of PAI-1 mRNA expression, compared with Glyceraldehyde 3-phosphate dehydrogenase, was measured post-TGF- β -treatment. * $P < 0.05$, # $P > 0.05$ values in a,b,c,i, and k are the means $\pm$ s.d. ($n = 3$). Statistical data analysis was performed using Student's *t*-test.

Moreover, overexpressing WT-CYLD markedly reduced expression of both endogenous and exogenous Smad3, but not Smad4 proteins (Fig. 3h), but had no effect on the levels of Smad3 mRNA (Fig. 3i). Interestingly, treatment with MG132, a specific proteasome inhibitor, reversed the WT-CYLD-induced decrease in Smad3 protein level (Fig. 3j) and TGF- β -induced PAI-1 expression (Fig. 3k). Collectively, these data suggest that CYLD inhibits TGF- β -signalling by decreasing stability of Smad3 protein in a proteasome-dependent manner.

CYLD decreases Smad3 stability via Akt-GSK3 β -CHIP pathway. Because CYLD is a known deubiquitinating enzyme (DUB)^{22–29}, we investigated whether CYLD-induced Smad3 degradation depends on its deubiquitinating activity. We first assessed the effect of DUB-deficient CYLD mutants on Smad3 basal level and TGF- β -induced SBE promoter activity. As shown in Fig. 4a, DUB-deficient CYLD mutants (H/N-CYLD and C/S-CYLD) failed to induce Smad3 degradation as compared with WT-CYLD. Similar

Figure 4 | CYLD decreases stability of Smad3 protein in a GSK3β-CHIP-dependent manner possibly via Akt. (a) Cells transfected with WT-CYLD or DUB-deficient mutants (H/N-CYLD or C/S-CYLD) were analysed by immunoblotting with the indicated antibodies. (b) SBE-promoter activity was determined in cells transfected with WT-CYLD, H/N-CYLD or C/S-CYLD stimulated with TGF-β. (c) Cells co-transfected with siCon or siCHIP with WT-CYLD or H/N-CYLD were analysed by immunoblotting with the indicated antibodies. (d) SBE-promoter activity was determined in cells co-transfected with siCon or siCHIP with WT-CYLD stimulated with TGF-β. (e) Relative quantity of PAI-1 mRNA expression compared with Glyceraldehyde 3-phosphate dehydrogenase was measured in cells co-transfected with siCon or siCHIP with WT-CYLD stimulated with TGF-β. (f) Cells transfected with control vector, WT-CYLD or DUB-deficient H/N-CYLD were treated with vehicle control or GSK3β-inhibitor SB216763 (5 μM) for 12 h and analysed by immunoblotting with the indicated antibodies. (g) Cells transfected with control vector or WT-CYLD were pre-treated with GSK3β-inhibitor (5 μM) for 2 h, followed by TGF-β-stimulation, and SBE-promoter activity was then determined. (h) Recombinant GSK3β protein (His-GSK3β) was incubated either with GST or recombinant CHIP protein (GST-CHIP) *in vitro*. CHIP was pulled down with Sepharose 4B beads and immunoblotted against His to detect GSK3β. (i) HA-GSK3β in cells co-transfected with Myc-CHIP and HA-GSK3β was pulled down with HA probe and analysed by immunoblotting with anti-Myc antibody. (j) A549 cells were treated with *S. pneumoniae* for various times as indicated in the figure, and cell lysates were analysed by immunoblotting with the indicated antibodies. (k) MEF cells from *Cyld*^{+/+} and *Cyld*^{-/-} mice were treated with *S. pneumoniae* for 30 min, and cell lysates were analysed by immunoblotting with the indicated antibodies. (l) WT mice were i.t. inoculated with *S. pneumoniae* for various times as indicated in the figure, and proteins from lung tissues were analysed by immunoblotting with the indicated antibodies. (m) A549 cells were treated with *S. pneumoniae* for various times as indicated, and cell lysates were analysed by immunoblotting with the indicated antibodies. **P* < 0.05 values in **b**, **d**, **e**, and **g** are the means ± s.d. (*n* = 3). Statistical data analysis was performed using Student's *t*-test. *S.p.*, *Streptococcus pneumoniae*.

result was also observed in TGF- β -induced SBE promoter activity (Fig. 4b). These data suggest that CYLD decreases Smad3 stability in a DUB activity-dependent manner.

Because E3 ubiquitin ligase has a critical role in mediating Smad3 degradation³⁰ and CYLD is known as a deubiquitinase^{22,28,29}, we hypothesized that CYLD may decrease Smad3 stability via regulating an E3 ubiquitin ligase. On the basis that carboxy terminus of CHIP has been shown to mediate Smad3 degradation^{31,32}, we first determined whether CHIP mediates CYLD-induced Smad3 degradation by using siCHIP. The efficiency of siCHIP in reducing CHIP expression was first confirmed in A549 cells (Supplementary Fig. S4). As shown in Fig. 4c, CHIP knockdown using siCHIP reversed the WT-CYLD-induced Smad3 decrease in A549 cells. Similar results were also observed in TGF- β -induced SBE promoter activity and PAI-1 upregulation (Fig. 4d,e, respectively). We next examined whether CYLD directly interacts with CHIP by performing co-immunoprecipitation experiments. As shown in Supplementary Fig. S5, no direct physical interaction was observed between CYLD and CHIP, thereby suggesting that CYLD may regulate CHIP-dependent Smad3 stability probably by targeting an upstream molecule of CHIP.

In view of the known upstream signalling, molecules involved in mediating Smad3 degradation, GSK3 β was shown to have an important role in mediating Smad3 degradation³³. We thus determined whether GSK3 β is involved in mediating CYLD-induced Smad3 degradation. As shown in Fig. 4f, a specific GSK3 β inhibitor SB216763 reversed the WT-CYLD-induced Smad3 decrease in A549 cells. Similar results were also observed in TGF- β -induced SBE promoter activity (Fig. 4g), thereby suggesting the involvement of GSK3 β in mediating regulation of Smad3 stability by CYLD. We further performed co-immunoprecipitation experiments to determine whether GSK3 β directly interacts with CYLD. As shown in Supplementary Fig. S5, no direct interaction was found between GSK3 β and CYLD, suggesting the involvement of an additional signalling molecule, further upstream of GSK3 β . It is interesting to note that GSK3 β was found to directly interact with CHIP both *in vitro* and *in vivo* (Fig. 4h,i). Further experiments demonstrate that GSK3 β phosphorylation was induced by *S. pneumoniae* and enhanced by CYLD deficiency (Fig. 4j,k). As phosphorylation of GSK3 β is known to result in inactivation of its kinase activity and CYLD deficiency enhances GSK3 β phosphorylation, it is logical that CYLD may induce GSK3 β kinase activity by inhibiting its phosphorylation and thereby promoting GSK3 β -CHIP-mediated Smad3 protein degradation. However, it still remains unclear how GSK3 β regulates CHIP-mediated Smad3 protein degradation. Previously, it has been reported that Erk5 MAPK regulates E3 ligase activity of CHIP dependently on Erk5 kinase activity³⁴. Thus, it is likely that GSK3 β may regulate E3 ligase activity of CHIP by binding to CHIP dependently on GSK3 β kinase activity. Further investigation is needed for understanding the molecular mechanism underlying GSK3 β -mediated regulation of CHIP E3 ligase activity.

We next sought to determine the direct molecular target of CYLD in mediating GSK3 β -dependent Smad3 protein degradation. Because Akt is known as the major upstream regulator of GSK3 β ^{35,36}, we investigated whether Akt mediates CYLD-induced degradation of Smad3. We first determined whether *S. pneumoniae* induces activation of Akt. As shown in Fig. 4j–l, *S. pneumoniae* induced phosphorylation of Akt and GSK3 β , but not p70S6K, which represents another downstream target of PI3K pathway, suggesting the specific activation of Akt–GSK3 β by *S. pneumoniae*. Consistent with these results, *S. pneumoniae* also upregulated Smad3 protein expression in a time-dependent manner (Fig. 4m). This interesting result thus led us to determine whether Akt is critically involved in mediating CYLD-induced degradation of Smad3 by first examining the effect of Akt knockdown on Smad3 protein stability.

CYLD decreases Smad3 stability by inhibiting Akt. As shown in Supplementary Fig. S6a, Akt1 and 2 but not 3 are predominantly expressed in both *Cyld*^{+/+} and *Cyld*^{-/-} cells. Thus, we determined the effect of knockdown of both Akt1 and 2 on Smad3 protein level in these cells. As shown in Fig. 5a, knockdown of Akt1/2 significantly reduced Smad3 protein expression in both WT and *Cyld*-deficient cells. Consistent with this result, Akt knockdown also inhibited the enhancement of TGF- β -induced SBE promoter activity induced by CYLD knockdown (Fig. 5b). Similarly, enhanced TGF- β -induced SBE promoter activity was also inhibited by Akt-specific inhibitor in *Cyld*^{-/-} MEFs (Fig. 5c). Moreover, TGF- β -induced PAI-1 mRNA expression was also markedly reduced by Akt1-deficiency in *Akt1*^{-/-} cells, and siCYLD no longer enhanced TGF- β -induced PAI-1 expression in *Akt1*^{-/-} cells (Supplementary Fig. S6b). We further confirmed whether activation of Akt does induce upregulation of fibrotic response gene expression via Smad3. As shown in Supplementary Fig. S7, activation of Akt by expressing a constitutively active C/A-Akt indeed induced expression of PAI-1 and CTGF in *Smad3*^{+/+} cells, but not in *Smad3*^{-/-} cells. Together, these data provide supportive evidence for the critical involvement of Akt in mediating CYLD-dependent Smad3 degradation. PI3K is known as the one of the major signalling molecules upstream of Akt. We thus determined whether PI3K, like Akt, is also involved in mediating CYLD-dependent Smad3 degradation by evaluating the effect of PI3K and Akt inhibitors on Smad3 protein expression. Akt inhibitor markedly reduced Smad3 protein expression whereas PI3K inhibitor LY294002 did not reduce Smad3 protein expression (Fig. 5d,e). These results are rather unexpected as it is well known that PI3K and, in turn, PIP3 is completely rate-limiting for Akt activation³⁷. Because only chemical inhibitors for PI3K were used in our studies, our data do not completely preclude the possible involvement of PI3K in regulating Akt-mediated regulation of Smad3. Further studies are needed to determine whether CYLD–Akt-mediated regulation of Smad3 is indeed independent of PI3K by using more specific approaches. Nonetheless, these data suggest that CYLD decreases Smad3 protein stability via negatively regulating Akt.

To further determine how CYLD negatively regulates Akt, we first examined whether CYLD physically interacts with Akt by performing co-immunoprecipitation experiments. Results in Fig. 5f showed that CYLD and Akt are indeed physically associated with each other in epithelial cells co-transfected with HA-CYLD and Flag-Akt. We next determined whether endogenous CYLD directly interacts with endogenous Akt and if such a direct interaction is further increased on *S. pneumoniae* treatment by performing Duolink *in vivo* protein–protein interaction detection assay^{38,39} and co-immunoprecipitation assay. As shown in Fig. 5g,h, endogenous CYLD indeed directly interacts with endogenous Akt and *S. pneumoniae* treatment increased their direct interaction. Together, these data suggest that CYLD decreases Smad3 stability and TGF- β -signalling by inhibiting Akt.

CYLD deubiquitinates K63-ubiquitinated Akt to inhibit Smad3. Because CYLD is a known deubiquitinase and Akt ubiquitination is critical for its functional activity⁴⁰, we next investigated whether CYLD deubiquitinates Akt. As shown in Fig. 6a, co-expressing WT-CYLD, but not DUB mutant (H/N-CYLD), decreased Akt polyubiquitination. In addition, siCYLD also markedly enhanced *S. pneumoniae*-induced Akt ubiquitination in epithelial cells (Fig. 6b). We then determined whether *S. pneumoniae* induces endogenous Akt ubiquitination in the absence and presence of CYLD. As shown in Fig. 6c,d; Supplementary Fig. S8, endogenous Akt ubiquitination was detected in the absence of *S. pneumoniae*, and *S. pneumoniae* markedly enhanced endogenous Akt ubiquitination. Interestingly, expression of WT-CYLD greatly decreased *S. pneumoniae*-induced endogenous Akt ubiquitination, whereas CYLD knockdown, or

Figure 5 | CYLD decreases Smad3 stability by inhibiting Akt. (a) MEF cells from *Cyld*^{+/+} and *Cyld*^{-/-} mice were transfected with siCon or siAkt1/2 and analysed by immunoblotting with the indicated antibodies. (b) SBE-promoter activity was determined in siCYLD-transfected A549 cells with or without siAkt co-transfection and stimulated with TGF-β. (c) SBE-promoter activity was determined in MEFs from *Cyld*^{+/+} and *Cyld*^{-/-} mice pretreated with Akt inhibitor and stimulated with TGF-β. (d) MEF cells from *Cyld*^{+/+} and *Cyld*^{-/-} mice were incubated with Akt inhibitor (20 μM), and cell lysates were analysed by immunoblotting with the indicated antibodies. (e) Cells were incubated with Akt inhibitor (20 μM) or LY294002 (20 μM), and cell lysates were analysed by immunoblotting with the indicated antibodies. (f) Lysates from cells transfected with HA-CYLD and Flag-Akt were immunoprecipitated with anti-CYLD antibody (upper panel) or anti-Akt antibody (lower panel), and interacting proteins were analysed by immunoblotting. (g) A549 cells were treated with *S. pneumoniae* for various times as indicated in the figure, stained with rabbit anti-CYLD antibody and/or mouse anti-Akt antibody, and *in vivo* protein-protein interaction between CYLD and Akt (Red dot) was detected with secondary proximity probes, anti-Rabbit MINUS and anti-mouse-PLUS, using Duolink *in vivo* protein-protein interaction detection kit (Olink). Scale bar, 10 μm. (h) Cells were treated with *S. pneumoniae* or vehicle control. Akt in cell lysates was pulled down with anti-Akt antibody and immunoblotted against CYLD and Akt. **P* < 0.05 values in b,c are the means ± s.d. (*n* = 3). Statistical data analysis was performed using Student's *t*-test. *S.p.*, *Streptococcus pneumoniae*.

CYLD deficiency, enhanced it. Because Akt has been shown to undergo K63 polyubiquitination, we next determined whether CYLD specifically deubiquitinates K63-polyubiquitinated Akt. As shown in Fig. 6e, co-expressing WT-CYLD markedly decreased K63- but not K48-polyubiquitinated Akt. Consistently, results in Fig. 6f indicate that recombinant CYLD protein (GST-rCYLD) directly deubiquitinates K63-linked polyubiquitination of Akt (His-Akt) *in vitro* in a cell-free system in a dose-dependent manner. Moreover, deficiency of CYLD also enhanced *S. pneumoniae*-induced K63-polyubiquitination of Akt (Fig. 6g). Taken together, these data provide strong evidence that CYLD negatively regulates Akt by directly interacting with and deubiquitinating K63-polyubiquitinated Akt, both *in vitro* in a cell-free system and *in vivo* under endogenous condition.

Because K14 lysine in the pleckstrin homology domain of Akt is critical for mediating its function⁴⁰, we next determined whether

mutation of K14 lysine to arginine (R) reduces polyubiquitination of Akt. Indeed, K14R, but not K8R, K20R and K30R, markedly reduced K63-linked polyubiquitination of Akt compared with WT-Akt (Fig. 6h). We further determined whether K14 residue in Akt is indeed functionally critical for mediating CYLD-induced inhibition of TGF-β signalling. As shown in Fig. 6i, expressing WT-CYLD significantly inhibited TGF-β-induced SBE promoter activity in epithelial cells co-transfected with WT-Akt or K20R, but not with K14R, thereby demonstrating the critical role for K14 in the PH domain of Akt in mediating inhibition of TGF-β signalling by CYLD. TNF receptor-associated factor 6 (TRAF6) was previously shown to function as an E3 ligase for Akt-K63 polyubiquitination and CYLD deubiquitinates TRAF6 (refs 24, 40). Thus, we next explored the possibility that CYLD may inhibit Akt-mediated fibrotic response via deubiquitinating TRAF6. As shown in Supplementary Fig. S9, CYLD knockdown, using siCYLD, still

Figure 6 | CYLD deubiquitinates K63-polyubiquitinated Akt to reduce Smad3. (a) Lysates from A549 cells co-transfected with HA-Ub WT, Flag-Akt WT, Flag-WT-CYLD or Flag-H/N-CYLD were immunoprecipitated with anti-Akt antibody and analysed by immunoblotting with the indicated antibodies. (b) Cells were co-transfected with Flag-Akt, HA-CYLD, or siCYLD and treated with *S. pneumoniae*. Akt was pulled down with Flag probe and immunoblotted against Ubiquitin (Ub), Akt, and CYLD. (c) Cells transfected with control vector or Flag-WT-CYLD were treated with *S. pneumoniae*, and cell lysates were immunoprecipitated with anti-Akt1 antibody and analysed by immunoblotting with the indicated antibodies. (d) CYLD-depleted cells using siCYLD were treated with *S. pneumoniae*, and Akt in cell lysates was pulled down with anti-Akt antibody and immunoblotted against Ub, Akt, and CYLD. (e) Lysates from A549 cells co-transfected with Flag-Akt WT, Flag-WT-CYLD, HA-Ub WT, HA-Ub K63, or HA-Ub K48 were immunoprecipitated with anti-Akt antibody, and analysed by immunoblotting with the indicated antibodies. (f) Recombinant Akt1 (His-rAkt1) was incubated with recombinant K63 ubiquitin (His-rUb-K63) with or without recombinant CYLD (GST-rCYLD) in *in vitro* ubiquitination assay buffer (BostonBiochem) and analysed by immunoblotting with the indicated antibodies. (g) MEF cells from *Cyld*^{+/+} and *Cyld*^{-/-} mice were co-transfected with Flag-Akt and HA-Ub K63, and treated with *S. pneumoniae*. Akt in cell lysate was pulled down with Flag probe and immunoblotted against Ub and Akt. (h) Lysates from cells co-transfected with HA-Ub K63, Flag-Akt WT, or Flag-Akt KR mutants (K8R, K14R, K20R or K30R) were immunoprecipitated with anti-Flag probe and analysed by immunoblotting with the indicated antibodies. (i) SBE-promoter activity was determined in A549 cells co-transfected with WT-CYLD, Akt WT, Akt K14R or Akt K20R stimulated with TGF- β . * $P < 0.05$, # $P > 0.05$ values in i are the means $\pm$ s.d. ($n = 3$). Statistical data analysis was performed using Student's *t*-test. *S.p.*, *Streptococcus pneumoniae*.

enhanced TGF- β -induced fibrotic response in TRAF6-depleted cells, thereby suggesting that CYLD inhibits Akt-mediated fibrotic response at least in part by directly interacting with and deubiquitinating Akt.

Discussion

To prevent the development of lung fibrosis during recovery of lung injury, wound-healing responses must be tightly regulated^{1,4-6}. The molecular mechanisms underlying this tight regulation remain largely unknown. In the present study, we provide evidences to iden-

tify CYLD deubiquitinase as a critical negative regulator for preventing development of lung fibrosis after infection with *S. pneumoniae*. CYLD inhibits TGF- β -signalling and thereby prevents fibrosis via decreasing stability of Smad3 protein in a GSK3 β -CHIP-dependent manner. Moreover, CYLD decreases Smad3 protein stability by directly deubiquitinating K63-polyubiquitinated Akt, which, in turn, leads to activation of GSK3 β (Fig. 7a). CYLD deficiency results in enhanced fibrotic response via enhanced Smad3-protein stability following lung injury (Fig. 7b). Taken together, as shown in our previous study¹, CYLD promotes bacteria-induced lung injury and

reduces host survival by inhibiting *S. pneumoniae*-induced PAI-1 expression via specific inhibition of p38 signalling during early lung-injury stage of infection; and as shown in our current study, CYLD prevents the development of lung fibrosis by inhibiting TGF- β -Smad signalling via reducing Smad3 stability during late tissue remodelling stage of infection. Thus, CYLD acts a key regulator during the entire wound-healing process in lung injury^{1,41}. These studies may help develop new therapeutic strategy for preventing lung fibrosis.

Previously it has been known that TNF receptor-associated factor 6 (TRAF6) acts as an E3 ligase for Akt-K63 polyubiquitination, and CYLD deubiquitinates TRAF6 (refs 24, 40). In this study we provided experimental evidences for direct interaction between Akt and CYLD, and also showed that CYLD does directly deubiquitinate Akt under both endogenous and exogenous conditions. It is possible that CYLD may inhibit Akt-mediated fibrotic response by actually deubiquitinating TRAF6. Thus, we evaluated the effect of siCYLD on TGF- β -induced fibrotic response in TRAF6-depleted cells using siTRAF6. Interestingly, CYLD knockdown still led to the enhancement of TGF- β -induced fibrotic response in TRAF6-depleted cells (Supplementary Fig. S9). Nonetheless, these data demonstrate that CYLD indeed inhibits Akt-mediated fibrotic response by at least in part directly interacting with and deubiquitinating Akt.

Here we have provided strong evidence that CYLD inhibits *S. pneumoniae*-induced Smad3-dependent fibrosis via inhibiting Akt, thereby linking CYLD to Smad3 via Akt. It is still unclear whether or not direct activation of Akt induces fibrotic response via Smad3. Indeed, direct activation of Akt by expressing a constitutively active form of C/A-Akt induces expression of fibrotic response gene PAI-1 and CTGF in *Smad3*^{+/+} cells, but not in *Smad3*^{-/-} cells (Supplementary Fig. S7). Collectively, it is evident that the fibrotic effects of CYLD-dependent Akt deubiquitination are indeed specifically mediated via the TGF- β -Smad3 pathway.

On the basis of the experimental data we presented, it is clear that CYLD regulates lung fibrosis by inhibiting TGF- β -signalling in wound-healing response in lung injury caused by infectious agents. Because TGF- β -signalling has an essential role in regulating tissue fibrotic response, it is possible that CYLD may also be crucial for negatively regulating fibrotic response induced by other injurious stimuli such as caustic chemicals. Thus, we sought to determine whether CYLD also acts as a key negative regulator for chemical-induced lung fibrosis in a widely used lung fibrosis model induced by bleomycin. Interestingly, CYLD deficiency markedly enhanced bleomycin-induced lung fibrosis in *Cyld*-deficient mice (Supplementary Fig. S3). These data thus suggest that the inhibitory effect of CYLD in fibrotic response may be generalizable for tissue fibrosis induced not only by infectious agents but also by other injurious stimuli such as caustic chemicals, as long as the fibrotic response is mainly mediated via TGF- β -Smad signalling.

Methods

Cell culture and reagents. A549, HeLa and HEK293 cells were maintained in the F12-K, minimal essential medium Eagle's with Earle's balanced salt solution (EMEM), and DMEM, respectively. WT mink Mv1Lu cells and two mutant cell lines DR26 and R1B cells were maintained with EMEM supplemented with nonessential amino acids. MEFs from *Smad3*^{-/-}, *Cyld*^{+/+} and *Cyld*^{-/-} mice were maintained in DMEM. Human primary bronchial epithelial NHBE (Cambrex) cells were maintained in bronchial epithelial growth media supplemented with bronchial epithelial growth media single Quot^{1,24,42,43}. Recombinant TGF- β 1 (indicated as TGF- β throughout the manuscript) and TNF- α were purchased from R&D system; Akt inhibitor (1L6-Hydroxymethyl-chiro-inositol-2(R)-2-O-methyl-3-O-octadecyl-sn-glycerocarbonate)^{44,45} and SB203580 were from Calbiochem; SB431542 and bleomycin were from Sigma; MG132 was from American Peptide. In vitro ubiquitination and deubiquitination assay kit was purchased from Boston Biochem. Duolink in vivo protein-protein interaction detection assay kit was from Olink Bioscience^{38,39}. Recombinant His-Akt and His-GSK3 β were from Calbiochem. ELISA assay kits for TGF- β and total and phospho-p38 MAPK were purchased from R&D system and Invitrogen, respectively.

Figure 7 | A schematic model illustrating a critical role of CYLD in lung fibrosis. (a,b) On the one hand, following lung injury after severe bacterial infection, for example, *S. pneumoniae* infection, extracellular matrix production and tissue recovery process are initiated via both T β RII/1-mediated activation of Smad3 and Akt-dependent inhibition of GSK3 β -CHIP-mediated Smad3 degradation. On the other hand, CYLD induced by *S. pneumoniae* inhibits Akt by deubiquitinating K63-polyubiquitinated Akt, which in turn leads to activation of GSK3 β and promotes CHIP-mediated Smad3 degradation, thereby attenuating excessive fibrotic response and preventing lung fibrosis (a). Deficiency of Cyld results in enhanced activation of Akt, which in turn leads to inhibition of GSK3 β and CHIP-mediated Smad3 degradation, thereby promoting excessive fibrotic response and tissue fibrosis (b). ECM, extracellular matrix; T β RII/1, TGF- β receptor II and I.

Real-time quantitative RT-PCR analysis. Total RNA was isolated using TRIzol reagent following manufacturer's instructions. Synthesis of complementary DNA from total RNA was performed with MultiScribe reverse transcriptase. Real-time quantitative PCR was performed using an ABI 7500 Sequence Detection System (Applied Biosystems)²⁴. Relative quantities of mRNAs were calculated using the comparative threshold cycle method and normalized using human and mouse glyceraldehyde-3-phosphate dehydrogenase as an endogenous control. The primer sequences for mouse COL1A2, COL3A1, CTGF and PAI-1, and human PAI-1, CHIP, and Smad3 are as follows¹⁰⁻¹². Mouse CTGF: 5'-GTAACCGGGGAGGGAAATTA-3' and 5'-ACAGCTGGACTCAGCCTCAT-3'; mouse COL1A2: 5'-GACAAATGAATGGGGCAAG-3' and 5'-CAATGTCCAGAGGTGCAATG-3'; mouse COL3A1: 5'-CGAAGATGGCAAAGATGGAT-3' and 5'-GCCACTAGGACCCCTTTCTC-3'; mouse PAI-1: 5'-GTAGCACAGGCACTGCAAAA-3' and 5'-TGAGATGACAAAGGTGTGG-3'; human PAI-1: 5'-CCCTTTGCAAGGATGGAAC-3' and 5'-ATGGCAATGTGACTGGAACA-3'; human CHIP: 5'-CCCGGCCCTATACATAGTT-3' and 5'-CAGTCCAGAGTCCAACAGCA-3'.

Plasmids and luciferase assays. The expression plasmids Flag-WT-CYLD, HA-WT-CYLD, Flag-H/N-CYLD, HA-C/S-CYLD, Flag-WT-Smad3, C/A-T β RI, and the reporter plasmids SBE-Luc, PAI-1-Luc, and NF- κ B-Luc were previously described^{17,42,43,46}. Flag-WT-Akt1, pRK5-HA-Ub WT, pRK5-HA-Ub K63, and pRK5-HA-Ub K48 were from Addgene, and K to R mutants of Akt were generated with WT-Akt1 using QuickChange XL Site-Directed Mutagenesis kit (Stratagene). All transient transfections were carried out using TransIT-LT1 reagent (Mirus) or Lipofectamine (Invitrogen) according to manufacturers' instructions²⁴.

RNA-mediated interference. RNA-mediated Interference for downregulating CYLD expression was carried out using pSuper-CYLD²⁴ and the sequence for the siCYLD is 5'-GATCCCCGAGCTACTGAGGACAGAAATTCAGAGATTCTGTCTCCTCAGTAGCTCTTTTGGAAA-3'. Human and mouse siRNAs for Akt and CHIP were from Dharmacon, and knockdown of Akt and CHIP, using siAkt and siCHIP, was performed with Lipofectamine 2000 (Invitrogen). ON-TARGETplus SMARTpool of siRNAs targeting human Akt1, human CHIP, mouse Akt1, and mouse Akt2 consists of four siRNAs and sequences for the siRNAs are as follows: Human siAkt1 (5'-CAUCACACCACCGACCAA-3', 5'-ACAAGGACGGGCACAUAUA-3', 5'-CAAGGGCACUUUCGGCAAG-3', 5'-UCACAGCCUGAAGUACUC-3'); human CHIP (5'-CGCUGGUGGC

CGUGUAUUA-3', 5'-GUGGAGGACUACUGAGGUU-3', 5'-GAAGGAGGUUA UUGACGCA-3', 5'-UGGAAGAGUGCCAGCGAAA-3'); mouse Akt1 (5'-CUG CAGAACUCUAGGAUC-3', 5'-GAUCAAGGAUGGUGCCACU-3', 5'-GAGG UUGCCACACGCUUA-3', 5'-CGACGUAGCCAUUGUGAA-3'); mouse Akt2 (5'-CCAUGAAUGACUUCGAUUA-3', 5'-GUACUUUGAUGACGAGUUC-3', 5'-CCUGAACAAUUCUCUGUA-3', 5'-GAUGCGGGCUAUCCAGAUG-3').

Western blot and ubiquitination experiments. Western blot, immunoprecipitation and ubiquitination experiments were performed as follows²⁴. Western blots were performed using whole-cell extracts, separated on 8 or 10% SDS-PAGE gels, and transferred to polyvinylidene difluoride membranes. The membrane was blocked with a solution of PBS containing 0.1% Tween 20 (PBS-T) and 5% BSA. The membrane was then incubated in a 1:2,000 dilution of a primary antibody in 5% BSA-PBS-T. After three washes in PBS-T, the membrane was incubated with 1:5,000 dilution of the corresponding secondary antibody in 3% non-fat skim milk-PBS-T. Respective proteins were visualized by using enhanced chemiluminescence detection reagents, according to the manufacturer's instructions. To conduct immunoprecipitation analysis, cell lysates were incubated with 1 µg of primary antibodies overnight, at 4°C, followed by 2-h incubation with protein A/G-agarose beads (Invitrogen). Immunoprecipitates were then suspended in a sample buffer, separated on 8% SDS-PAGE, transferred to polyvinylidene difluoride membrane, and detected by immunoblot analysis, as described above. The antibodies against total-Akt, phospho-Akt at T308 & S473, total Smad3, phospho-Smad3, total p70S6K, phospho-p70S6K at T389, total GSK3β, phospho-GSK3β at S9, mouse HA-Tag, His-Tag, and mouse and rabbit anti-Ubiquitin were purchased from Cell Signaling; antibodies against CYLD, total-Akt1/2/3, goat total-Akt1, Smad4, rabbit HA-Tag, mouse Ubiquitin, and actin were from Santa Cruz; FLAG and β-actin were from Sigma.

In vivo protein-protein interaction detection assay. A549 cells were cultured in tissue culture slide and incubated with *S. pneumoniae*, or control for time indicated in the figure. Cells were stained with 2 µg ml⁻¹ of primary mouse anti-Akt antibody and rabbit anti-CYLD antibody, and protein-protein interaction between Akt and CYLD was detected with secondary proximity probes, anti-Rabbit MINUS and anti-mouse PLUS, using Duolink *in vivo* protein-protein interaction detection assay kit, according to the manufacturer's instructions (Duolink proximity ligation assay, Olink Bioscience)^{38,39}.

Mice and animal experiments. *Cyld*^{-/-} mice were generated by homologous recombination as follows¹. The targeting construct was designed to disrupt the exons 2 and 3 with an IRES-LacZ/MC1-Neo cassette. The targeting plasmid was linearized and transfected into embryonic stem cells of a 129/S. Homologously recombined embryonic stem cells were injected into blastocysts that were subsequently transferred to foster mothers, to generate chimeric progeny. Generated chimeric progeny were backcrossed to C57BL/6J, and germline transmission was confirmed by PCR with tail DNA. Homozygous knockout of *Cyld* gene was confirmed by mRNA detection by RT-PCR and CYLD protein detection by western blot analysis in MEF cells and lung tissues. For *S. pneumoniae*-induced severe infections in WT and *Cyld*^{-/-} mice, anaesthetized mice were intratracheally (i.t.) inoculated with live *S. pneumoniae* (5 × 10⁷ CFU per mouse). Survived mice from severe pneumonia were then sacrificed 2 weeks post *S. pneumoniae* infection for histopathological analysis. For TGF-β inoculation, anaesthetized WT and *Cyld*^{-/-} mice were i.t. inoculated with TGF-β (25–100 ng per mouse) for 6 h, and lung tissues were then subjected to total mRNA and protein extraction. In experiments using chemical inhibitor, SB431542 (10 mg kg⁻¹) or SB203580 (20 mg kg⁻¹) or equal volume of vehicle control was administered via an intraperitoneal route 1–2 h(s) before the i.t. inoculation of *S. pneumoniae*. For bleomycin-induced fibrosis model, animals were i.t. inoculated with bleomycin (3 units per kg body weight) for 2 weeks. Lung tissues were then subjected to histological analysis and total mRNA and protein extraction. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at University of Rochester and Georgia State University.

Histology and immunohistochemistry. Lung tissue sections from WT and *Cyld*^{-/-} mice and normal control and pulmonary fibrosis patients were stained with haematoxylin and eosin (H&E), to visualize lung inflammation, and Masson's trichrome staining (Trichrome staining) was performed to highlight organizing fibrosis. Immunohistochemical staining against CYLD and Smad3 was performed using ABC staining System (Santa Cruz). Briefly, tissue sections were incubated with 1 µg of primary antibodies or control IgG followed by 3 washes with PBS. Tissues were then incubated with 1 µg of biotinylated secondary antibodies followed by the incubation with AB enzyme reagent. After three washes, colour reaction was developed with peroxidase substrate. Control and fibrotic lung tissues from patients were obtained from Chonnam National Hospital with approval from the Institutional Review Board (IRB) at Chonnam National University, Korea.

Statistical analysis. All experiments were repeated at least three times with consistent results. Data are means ± s.d. Statistical significance was assessed by two-tailed unpaired student's *t*-test. *P* < 0.05 was considered significant.

References

- Lim, J. H. *et al.* Tumor suppressor CYLD regulates acute lung injury in lethal *Streptococcus pneumoniae* infections. *Immunity* **27**, 349–360 (2007).
- Wallace, W. A., Fitch, P. M., Simpson, A. J. & Howie, S. E. Inflammation-associated remodelling and fibrosis in the lung - a process and an end point. *Int. J. Exp. Pathol.* **88**, 103–110 (2007).
- Zhang, K. & Phan, S. H. Cytokines and pulmonary fibrosis. *Biol. Signal.* **5**, 232–239 (1996).
- Tager, A. M. *et al.* The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. *Nat. Med.* **14**, 45–54 (2008).
- Rhodes, G. C., Lykke, A. W., Tapsall, J. W. & Smith, L. W. Abnormal alveolar epithelial repair associated with failure of resolution in experimental streptococcal pneumonia. *J. Pathol.* **159**, 245–253 (1989).
- Ley, K. & Zarbock, A. From lung injury to fibrosis. *Nat. Med.* **14**, 20–21 (2008).
- Ghosh, A. K. & Vaughan, D. E. PAI-1 in Tissue Fibrosis. *J. Cell. Physiol.* **227**, 493–507 (2012).
- Loskutoff, D. J. & Quigley, J. P. PAI-1, fibrosis, and the elusive provisional fibrin matrix. *J. Clin. Invest.* **106**, 1441–1443 (2000).
- Shetty, S., Padijnyayveetil, J., Tucker, T., Stankowska, D. & Idell, S. The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **295**, L967–975 (2008).
- Bonnaud, P. *et al.* Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. *J. Immunol.* **173**, 2099–2108 (2004).
- Izumi, N. *et al.* BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **290**, L120–126 (2006).
- Hattori, N. *et al.* Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. *J. Clin. Invest.* **106**, 1341–1350 (2000).
- Bonnaud, P. *et al.* TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. *J. Immunol.* **175**, 5390–5395 (2005).
- Lasky, J. A. & Brody, A. R. Interstitial fibrosis and growth factors. *Environ. Health Perspect.* **108**(Suppl 4), 751–762 (2000).
- Beisswenger, C., Coyne, C. B., Shchepetov, M. & Weiser, J. N. Role of p38 MAP kinase and transforming growth factor-beta signaling in transepithelial migration of invasive bacterial pathogens. *J. Biol. Chem.* **282**, 28700–28708 (2007).
- Bartram, U. & Speer, C. P. The role of transforming growth factor beta in lung development and disease. *Chest* **125**, 754–765 (2004).
- Yu, H. *et al.* Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis. *Faseb J.* **22**, 1778–1789 (2008).
- Feng, X. H. & Derynck, R. Specificity and versatility in tgf-beta signaling through Smads. *Annu. Rev. Cell Dev. Biol.* **21**, 659–693 (2005).
- Massague, J., Seoane, J. & Wotton, D. Smad transcription factors. *Genes Dev.* **19**, 2783–2810 (2005).
- ten Dijke, P. & Hill, C. S. New insights into TGF-beta-Smad signalling. *Trends Biochem. Sci.* **29**, 265–273 (2004).
- Laiho, M., Weis, M. B. & Massague, J. Concomitant loss of transforming growth factor (TGF)-beta receptor types I and II in TGF-beta-resistant cell mutants implicates both receptor types in signal transduction. *J. Biol. Chem.* **265**, 18518–18524 (1990).
- Brummelkamp, T. R., Nijman, S. M., Dirac, A. M. & Bernards, R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. *Nature* **424**, 797–801 (2003).
- Massoumi, R. Ubiquitin chain cleavage: CYLD at work. *Trends Biochem. Sci.* **35**, 392–399.
- Yoshida, H., Jono, H., Kai, H. & Li, J. D. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. *J. Biol. Chem.* **280**, 41111–41121 (2005).
- Massoumi, R., Chmielarska, K., Hennecke, K., Pfeifer, A. & Fassler, R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. *Cell* **125**, 665–677 (2006).
- Sun, S. C. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. *Cell Death Differ.* **17**, 25–34.
- Reiley, W. W. *et al.* Regulation of T cell development by the deubiquitinating enzyme CYLD. *Nat. Immunol.* **7**, 411–417 (2006).
- Trompouki, E. *et al.* CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. *Nature* **424**, 793–796 (2003).
- Kovalenko, A. *et al.* The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. *Nature* **424**, 801–805 (2003).
- Inoue, Y. & Imamura, T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. *Cancer Sci.* **99**, 2107–2112 (2008).
- Xin, H. *et al.* CHIP controls the sensitivity of transforming growth factor-beta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation. *J. Biol. Chem.* **280**, 20842–20850 (2005).

32. Li, L. *et al.* CHIP mediates degradation of Smad proteins and potentially regulates Smad-induced transcription. *Mol. Cell. Biol.* **24**, 856–864 (2004).
33. Guo, X. *et al.* Axin and GSK3- control Smad3 protein stability and modulate TGF- signaling. *Genes Dev.* **22**, 106–120 (2008).
34. Woo, C. H. *et al.* Novel role of C terminus of Hsc70-interacting protein (CHIP) ubiquitin ligase on inhibiting cardiac apoptosis and dysfunction via regulating ERK5-mediated degradation of inducible cAMP early repressor. *Faseb J.* **24**, 4917–4928.
35. Sutherland, C., Leighton, I. A. & Cohen, P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. *Biochem. J.* **296** (Part 1), 15–19 (1993).
36. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. & Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature* **378**, 785–789 (1995).
37. Yuan, T. L. & Cantley, L. C. PI3K pathway alterations in cancer: variations on a theme. *Oncogene* **27**, 5497–5510 (2008).
38. Mahmoudi, S. *et al.* WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodies. *PLoS Biol.* **8**, e1000521.
39. Coste, I. *et al.* Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. *J. Clin. Invest.* **120**, 3663–3667.
40. Yang, W. L. *et al.* The E3 ligase TRAF6 regulates Akt ubiquitination and activation. *Science* **325**, 1134–1138 (2009).
41. Trompouki, E. *et al.* Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. *Neoplasia* **11**, 469–476 (2009).
42. Jono, H. *et al.* Transforming growth factor-beta-Smad signaling pathway negatively regulates nontypeable *Haemophilus influenzae*-induced MUC5AC mucin transcription via mitogen-activated protein kinase (MAPK) phosphatase-1-dependent inhibition of p38 MAPK. *J. Biol. Chem.* **278**, 27811–27819 (2003).
43. Jono, H. *et al.* Transforming growth factor-beta -Smad signaling pathway cooperates with NF-kappa B to mediate nontypeable *Haemophilus influenzae*-induced MUC2 mucin transcription. *J. Biol. Chem.* **277**, 45547–45557 (2002).
44. Elia, U. & Flescher, E. PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells. *Neoplasia* **10**, 1303–1313 (2008).
45. Hu, Y. *et al.* 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. *J. Med. Chem.* **43**, 3045–3051 (2000).
46. Mikami, F. *et al.* The transforming growth factor-beta-Smad3/4 signaling pathway acts as a positive regulator for TLR2 induction by bacteria via a dual mechanism involving functional cooperation with NF-kappaB and MAPK phosphatase 1-dependent negative cross-talk with p38 MAPK. *J. Biol. Chem.* **281**, 22397–22408 (2006).

Acknowledgements

We are grateful to Drs. R. Bernards, G. Courtis, and J. Massague for kindly providing reagents. This work was supported in part by grants from National Institute of Health DC005843, AI073374 and DC004562 to J.D. Li, AHA 10SDG2630077 to J.H. Lim, CA108454, GM063773, and the National Natural Science Foundation of China (No. 3109360) to X.-H. Feng, HL077789 and HL088400 to C. Yan, the National Natural Science Foundation of China (No. 30825019) to H. Shen, the National Natural Science Foundation of China (No. 30972635) to Y.X. Huang, and the Key Technologies Research and Development Program for Infectious Disease of China (No. 2008ZX10003011) to W.H. Zhang.

Author contributions

J.H.L. and H.J. conceived, designed and performed experiments. K.K., C.H.W., J.L., M.M., T.M., X.X., K.S.H., P.B., T.K., and Hai.X. carried out experiments and analysed data. Y.H., W.Z., S.H.P., Y.I.K., Y.D.C., H.S., Hao.X., C.Y., L.F.C., B.W., and X.H.F. contributed reagents, materials, and data analysis. J.D.L. was responsible for overall study design and data analysis, and he wrote the manuscript and supervised the project.

Additional information

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Lim, J. H. *et al.* CYLD negatively regulates transforming growth factor- β -signalling via deubiquitinating Akt. *Nat. Commun.* **3**:771 doi: 10.1038/ncomms1776 (2012).

License: This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivative Works 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>